BioCryst to Report Second Quarter 2026 Financial Results on August 5
BioCryst (Nasdaq:BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq:BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update, with live and replay access via the investors section of the company website.
Details
News Market Reaction – BCRX
On Jul 22, the day this news came out, BCRX closed 0.96% above the previous close.
Data tracked by StockTitan Argus for the Jul 22 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results to be reported
- Results date
- August 5, 2026
- Scheduled financial-results announcement
- Conference call time
- 8:30 a.m. ET
- Scheduled webcast and conference call
Previous Earnings date Reports
-
Prior Q1 2026 earnings-date announcement scheduled the May 6 results release and webcast.
-
Prior Q4 2025 earnings-date announcement scheduled the February 26 results release and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.